SAN MATEO, Calif., Dec. 7 /PRNewswire-FirstCall/ -- NeurogesX, Inc.
(Nasdaq: NGSX), a biopharmaceutical company focused on developing novel
pain management therapies, announced today that Anthony DiTonno, President
and Chief Executive Officer, will participate in a panel discussion, titled
"No Pain, No Gain: New Approaches to Pain Treatment" at the RBC Capital
Markets Healthcare Conference. The panel discussion is scheduled for
Wednesday, December 12, 2007 at the Westin Times Square Hotel in New York,
Event: RBC Capital Markets Healthcare Conference
Date: Wednesday, December 12, 2007
Time: 9:00 a.m. ET
Place: The Westin Times Square Hotel, New York, NY
An audio Web cast of the Company's presentations will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, the timing of presentations by
NeurogesX and the expected benefits of NeurogesX' potential products,
including its lead product candidate NGX-4010. Such statements are based on
management's current expectations, but actual results may differ materially
due to various risks and uncertainties, including, but not limited to, past
results of clinical trials may not be indicative of future clinical trials
results; NeurogesX' product candidate may have unexpected adverse side
effects or inadequate therapeutic efficacy; positive results in clinical
trials may not be sufficient to obtain FDA or European regulatory approval;
physician or patient reluctance to use NGX-4010, if approved, or the
inability of physicians to obtain sufficient reimbursement for such
procedures; potential alternative therapies; maintaining adequate patent or
trade secret protection without violating the intellectual property rights
of others; and other difficulties or delays in clinical development,
obtaining regulatory approval, market acceptance and commercialization of
NGX-4010 and the advantages of NGX-4010 over other pain therapies. For
further information regarding these and other risks related to NeurogesX'
business, investors should consult NeurogesX' filings with the Securities
and Exchange Commission.
NeurogesX The Ruth Group
Stephen Ghiglieri Investors / Media
(650) 358-3310 Stephanie Carrington / Jason Rando
firstname.lastname@example.org (646) 536-7017 / 7025
|SOURCE NeurogesX, Inc.|
Copyright©2007 PR Newswire.
All rights reserved